Table I.
Patient characteristics at diagnosis with primary refractory PTCL (n = 93).
| Characteristic | No. | % |
|---|---|---|
| Age, years | ||
| > 60 | 33 | 35 |
| Gender | ||
| Male | 63 | 68 |
| Histology | ||
| PTCL, NOS | 40 | 43 |
| AITL | 17 | 18 |
| ALK(+) ALCL | 8 | 9 |
| ALK(−) and ALK-unknown ALCL | 16 | 17 |
| Other* | 12 | 13 |
| IPI | ||
| 0–1 | 17 | 18 |
| 2–3 | 47 | 51 |
| 4–5 | 20 | 22 |
| Missing | 9 | 9 |
| PIT | ||
| 0 | 11 | 12 |
| 1–2 | 54 | 58 |
| 3–4 | 19 | 20 |
| Missing | 9 | 9 |
| First line therapy | ||
| CHOP/CHOEP | 86 | 92 |
| Salvage therapy | ||
| Multi-agent regimens | 59 | 63 |
| ICE | 24 | 26 |
| DHAP | 6 | 6 |
| ESHAP | 10 | 11 |
| Other multi-agent | 19 | 20 |
| Single-agent regimens | 15 | 16 |
| Gemcitabine | 1 | 1 |
| Retinoid | 1 | 1 |
| Antimetabolite | 3 | 3 |
| Denileukin diftitox | 1 | 1 |
| Proteasome inhibitor | 4 | 4 |
| Brentuximab vedotin | 3 | 3 |
| HDAC inhibitor | 1 | 1 |
| Cyclosporine | 1 | 1 |
| Non-systemic therapies** | 19 | 20 |
| Stem-cell transplant | ||
| Autologous | 15 | 16 |
| Allogeneic | 20 | 22 |
PTCL, NOS, peripheral T-cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; IPI, International Prognostic Index; ECOG, Eastern Cooperative Oncology Group performance status; CHOP/CHOEP, cyclophosphamide, doxorubicin, vincristine, prednisone, +/− etoposide; ICE, ifosfamide, carboplatin, and etoposide; DHAP, dexamethasone, high-dose cytarabine, and cisplatin; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin.
Other histologies include extranodal NK/T-cell lymphoma (n=6), hepatosplenic T-cell lymphoma (n=2), and enteropathy-associated T-cell lymphoma (n=4).
Includes patients treated with local radiation alone, steroids alone, or observation/supportive care, as well as patients with unknown salvage therapy status.